US Patent Issued to CRYSTAL BIOSCIENCE on March 24 for "Human glucose-dependent insulinotropic polypeptide receptor (GIPR) antibodies and methods of use thereof to inhibit GIP receptor and signaling" (California Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,930, issued on March 24, was assigned to CRYSTAL BIOSCIENCE INC. (Emeryville, Calif.).

"Human glucose-dependent insulinotropic polypeptide receptor (GIPR) antibodies and methods of use thereof to inhibit GIP receptor and signaling" was invented by Shelley Izquierdo (Berkeley, Calif.), Shreya Pramanick (Emeryville, Calif.) and William Don Harriman (Alameda, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides antibodies that specifically bind to and in some cases inhibit the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The antibodies find use in a variety of treatment, diagnostic, and monitoring...